![(2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic Acid](https://veeprho.com/wp-content/uploads/2026/02/2R4S-5-Biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpentanoic-Acid-1012341-50-2-VE009680-ac14-sqr.png "(2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic Acid")
100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
1012341-50-2(2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic Acid
● In Stock
| Catalogue No.: | VE009680 |
|---|---|
| CAS No.: | 1012341-50-2 |
| Mol. Formula: | C23H29NO4 |
| Mol. Weight: | 383.48 g/mol |
Order Online
Additional information on CAS 1012341-50-2
Parent drug
SacubitrilIUPAC Name
(2R,4S)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methylpentanoic acidPharmacopeial Synonyms
N/ASynonyms
N/ASmiles
CC(CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)OC(C)(C)C)C(=O)OInChI
InChI=1S/C23H29NO4/c1-16(21(25)26)14-20(24-22(27)28-23(2,3)4)15-17-10-12-19(13-11-17)18-8-6-5-7-9-18/h5-13,16,20H,14-15H2,1-4H3,(H,24,27)(H,25,26)/t16-,20+/m1/s1Shipping Condition
Ambient TemperatureDescription
It is one of impurity present in Sacubitril, Sacubitril is a prodrug neprilysin inhibitor and is a neutral endopeptidase that would typically cleave natriuretic peptides, which includes atrial natriuretic peptide, brain natriuretic peptide, and c-type natriuretic peptide. they are released under atrial and ventricle stress, which activate downstream receptors leading to vasodilation, natriuresis, and diuresis. endothelin-1 and peptide amyloid beta-protein. Inhibition of neprilysin reduced breakdown and increased concentration of endogenous natriuretic peptides in addition to increased levels of vasoconstricting hormones such as angiotensin II, which reduce the risk of cardiovascular death and heart failure.References
Kaplinsky, E. (2016). Sacubitril/valsartan in heart failure: latest evidence and place in therapy. Therapeutic Advances in Chronic Disease, 7(6), 278–290. https://doi.org/10.1177/2040622316665350Request a Quote
"*" indicates required fields
Other products related to Sacubitril impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
